Ribociclib Extends Survival in HR+ Breast Cancer [News in Brief]

The CDK4/6 inhibitor plus standard therapy demonstrates effectiveness in premenopausal and perimenopausal women.

from Cancer via ola Kala on Inoreader http://ift.tt/2B6HvnS
via IFTTT